Jonathan Moggs
Overview
Explore the profile of Jonathan Moggs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
531
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alb M, Reiche K, Rade M, Sewald K, Loskill P, Cipriano M, et al.
J Immunotoxicol
. 2024 Dec;
21(sup1):S13-S28.
PMID: 39655500
The success of cellular immunotherapies such as chimeric antigen receptor (CAR) T cell therapy has led to their implementation as a revolutionary treatment option for cancer patients. However, the safe...
2.
Beil J, Perner J, Pfaller L, Gerard M, Piaia A, Doelemeyer A, et al.
Nat Commun
. 2023 Oct;
14(1):6353.
PMID: 37816736
The possibility that ancestral environmental exposure could result in adaptive inherited effects in mammals has been long debated. Numerous rodent models of transgenerational responses to various environmental factors have been...
3.
Carss K, Deaton A, Del Rio-Espinola A, Diogo D, Fielden M, Kulkarni D, et al.
Nat Rev Drug Discov
. 2022 Oct;
22(2):145-162.
PMID: 36261593
Human genetics research has discovered thousands of proteins associated with complex and rare diseases. Genome-wide association studies (GWAS) and studies of Mendelian disease have resulted in an increased understanding of...
4.
Huang Y, Sendzik M, Zhang J, Gao Z, Sun Y, Wang L, et al.
J Med Chem
. 2022 Mar;
65(7):5317-5333.
PMID: 35352560
Polycomb Repressive Complex 2 (PRC2) plays an important role in transcriptional regulation during animal development and in cell differentiation, and alteration of PRC2 activity has been associated with cancer. On...
5.
Axelsson E, Ljungvall I, Bhoumik P, Bas Conn L, Muren E, Ohlsson A, et al.
PLoS Genet
. 2022 Jan;
18(1):e1010039.
PMID: 35085237
[This corrects the article DOI: 10.1371/journal.pgen.1009726.].
6.
Axelsson E, Ljungvall I, Bhoumik P, Bas Conn L, Muren E, Ohlsson A, et al.
PLoS Genet
. 2021 Sep;
17(9):e1009726.
PMID: 34473707
Selective breeding for desirable traits in strictly controlled populations has generated an extraordinary diversity in canine morphology and behaviour, but has also led to loss of genetic variation and random...
7.
Tessier Y, Achanzar W, Mihalcik L, Amuzie C, Andersson P, Parry J, et al.
Nucleic Acid Ther
. 2020 Oct;
31(1):7-20.
PMID: 33054599
The Oligonucleotide Working Group of the European Federation of Pharmaceutical Industries and Associations (EFPIA) conducted a survey of companies to understand the trends in nonclinical practices and regulatory expectations for...
8.
Reynolds V, Butler P, Abernathy M, Aschenbrenner L, Best D, Blank J, et al.
Regul Toxicol Pharmacol
. 2020 Sep;
117:104746.
PMID: 32911461
Pharmaceutic products designed to perturb the function of epigenetic modulators have been approved by regulatory authorities for treatment of advanced cancer. While the predominant effort in epigenetic drug development continues...
9.
Yauk C, Harrill A, Ellinger-Ziegelbauer H, van der Laan J, Moggs J, Froetschl R, et al.
Regul Toxicol Pharmacol
. 2019 Nov;
110:104526.
PMID: 31726190
Robust genomic approaches are now available to realize improvements in efficiencies and translational relevance of cancer risk assessments for drugs and chemicals. Mechanistic and pathway data generated via genomics provide...
10.
Vitobello A, Perner J, Beil J, Zhu J, Del Rio-Espinola A, Morawiec L, et al.
Life Sci Alliance
. 2019 Oct;
2(5).
PMID: 31615920
Liver cancer susceptibility varies amongst humans and between experimental animal models because of multiple genetic and epigenetic factors. The molecular characterization of such susceptibilities has the potential to enhance cancer...